Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated RatsReport as inadecuate




Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats - Download this document for free, or read online. Document in PDF available to download.

Evidence-Based Complementary and Alternative Medicine - Volume 2015 2015, Article ID 948376, 10 pages -

Research Article

Department of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China

Department of Traditional Chinese Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, China

Department of Pediatrics, Southwest Hospital, Third Military Medical University, Chongqing 400038, China

Chongqing Academy of Chinese Material Medicine, Chongqing 400065, China

Received 29 September 2014; Revised 23 December 2014; Accepted 24 December 2014

Academic Editor: Sae Uchida

Copyright © 2015 Liangjun Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Swertianlarin is an herbal agent abundantly distributed in Swertia mussotii Franch, a Chinese traditional herb used for treatment of jaundice. To study the therapeutic effect of swertianlarin on cholestasis, liver injury, serum proinflammatory cytokines, and bile salt concentrations were measured by comparing rats treated with swertianlarin 100 mg-kg-d or saline for 3, 7, or 14 days after bile duct ligation BDL. Serum alanine aminotransferase ATL and aspartate aminotransferase AST levels were significantly decreased in BDL rats treated with swertianlarin for 14 days . The reduced liver injury in BDL rats by swertianlarin treatment for 14 days was further confirmed by liver histopathology. Levels of serum tumor necrosis factor alpha TNFα were decreased by swertianlarin in BDL rats for 3 and 7 days . Moreover, reductions in serum interleukins IL-1β and IL-6 levels were also observed in BDL rats treated with swertianlarin . In addition, most of serum toxic bile salt concentrations e.g., chenodeoxycholic acid CDCA and deoxycholic acid DCA in cholestatic rats were decreased by swertianlarin . In conclusion, the data suggest that swertianlarin derived from Swertia mussotii Franch attenuates liver injury, inflammation, and cholestasis in bile duct-ligated rats.





Author: Liangjun Zhang, Ying Cheng, Xiaohuang Du, Sheng Chen, Xinchan Feng, Yu Gao, Shaoxue Li, Li Liu, Mei Yang, Lei Chen, Zhih

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents